Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
Metrics to compare | 4883 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4883PeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −10.6x | −0.4x | |
PEG Ratio | −1.00 | −0.01 | 0.00 | |
Price/Book | 1.9x | 4.3x | 2.6x | |
Price / LTM Sales | - | 23.8x | 3.2x | |
Upside (Analyst Target) | - | 86.5% | 46.7% | |
Fair Value Upside | Unlock | 9.2% | 7.6% | Unlock |